AIM
LXRX icon

Acrospire Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Acrospire Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-9,931
Closed -$137K – 2366
2016
Q4 		$137K Sell
9,931
-1,164
-10% -$18.7K 0.06% 682
2016
Q3 		$200K Sell
11,095
-2,700
-20% -$43.5K 0.13% 160
2016
Q2 		$198K Sell
13,795
-3,888
-22% -$52.7K 0.15% 86
2016
Q1 		$211K Buy
+17,683
New +$185K 0.15% 179

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's LXRX Position: Q1 2017 in Review

Acrospire Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 9,931 shares — an estimated $137K sold.

Acrospire Investment Management first reported a position in LXRX in Q1 2016 and held it in 4 quarters. The position peaked at $211K in Q1 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

  • Acrospire Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 9,931 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $137K.
  • Acrospire Investment Management first reported a position in Lexicon Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Acrospire Investment Management's Lexicon Pharmaceuticals position peaked at $211K in Q1 2016.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.